n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, June 18th, 2015

The QualityStocks
Daily Stock List

graphic
graphic

OptimizeRx Corp. (OPRX)

Streetwise Reports and Bull in Advantage reported previously on OptimizeRx Corp. (OPRX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OptimizeRx Corp. provides innovative consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products. The Company does so while offering pharmaceutical and healthcare companies effective ways to expand awareness, access and adherence to their medications. Its core product is SampleMD. OptimizeRx lists on the OTC Markets Group’s OTCQB and the Company is headquartered in Rochester, Michigan.

OptimizeRx’s SampleMD replaces drug samples with electronic trial vouchers and copay coupon savings, which are electronically added to an e-Prescription and sent electronically to the pharmacy and is integrated within leading Electronic Health Record (EHR) platforms in the nation. These include Allscripts, Quest Diagnostics, Practice Fusion and more than 300 other EHRs to reach greater than 250,000 healthcare providers.

OptimizeRx promotes patients savings and support from the world's largest pharmaceutical companies. These include Pfizer, Lilly, Novartis, AstraZeneca and numerous others.

The Company has also launched OPTIMZEHR™. This is its consulting and implementation practice to assist both pharmaceutical-biotech companies and healthcare provider platforms in ascertaining and executing on mutually beneficial opportunities to jointly assist physicians and patients within their electronic health record (EHR) workflow.

OptimizeRx’s services include SAMPLEMD® E-Coupons; Patient Education; On-Demand Support; EHR Brand Messaging; New Product Launch/Drug File Integration; and EHR Sales Training. It initially launched its SampleMD e-coupon solution in April of this year within Practice Fusion's EMR. OptimizeRx expects to be fully integrated by the end of Q2.

The Company’s sales for the first three months of 2015 approached $1.5 million. This represents a 15 percent increase over the same period in 2014. It generated positive cash flow from operations of $86,692 during the quarter. Furthermore, its cash balance increased to greater than $3.5 million. Moreover, its balance sheet continued to improve with working capital of around $3.2 million and a working capital ratio of 2.5 to 1.

OptimizeRx continues to add new brands this year at existing customers such as AstraZenica and Lilly, and also at new customers such as Otsuka and Shionogi.

OptimizeRx Corp. (OPRX), closed Thursday's trading session at $0.99, up 7.61%, on 246,991 volume with 84 trades. The average volume for the last 60 days is 24,590 and the stock's 52-week low/high is $0.7623/$1.60.

Abakan, Inc. (ABKI)

TheMicrocapNews, StockBlogs, TheOTCInvestor, and RedChip reported previously on Abakan, Inc. (ABKI), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Abakan, Inc. is an emerging leader in the advanced coatings and metal formulations markets. The OTCQB-listed Company develops, manufactures, and markets advanced nano-composite materials, innovative fabricated metal products, and highly engineered metal composites. These are for applications in the oil and gas, petrochemical, mining, aerospace and defense, energy, infrastructure and processing industries. Abakan is based in Miami, Florida.

The Company expects to become a leader in the multi-billion dollar advanced coatings and metal formulations markets due to its investment in MesoCoat, Inc. and Powdermet, Inc. To date, Abakan has acquired a 52.5 percent controlling interest in MesoCoat and a 41 percent non-controlling interest in Powdermet. As Powdermet owns 47.5 percent of MesoCoat, Abakan’s interest in Powdermet represents an additional 19.5 percent indirect interest in MesoCoat.

Abakan’s technology portfolio presently includes high-speed, large-area metal cladding technology, and long-life nano-composite anti-corrosion and wear coating materials. The Company has introduced its PComP™ W for metal asset protection and life extension to the oil and gas and mining industries. Abakan is currently focused on the scale-up and commercialization of its highly disruptive metal cladding products for the oil and gas, oil sands, and mining industries. It currently operates from multiple locations in the U.S., and in Canada.

Last week, Abakan announced that its subsidiary, MesoCoat de Mexico S.A. de C.V., received its first commercial PComP order for the coating of certain large roller screens from one of the largest steel manufacturing and iron ore processing companies in Mexico. The expectation is that the initial order will be followed by repeat orders and an annual contract to coat all of the rolls used at the facility.

In addition, the Company has received orders for coating "lances" that are used heavily in iron ore production. Abakan anticipates trial orders for coating tuyeres, pumps, clad plates, turbines, as well as other manufacturing components.

Abakan, Inc. (ABKI), closed Thursday's trading session at $0.33, down 2.97%, on 14,385 volume with 6 trades. The average volume for the last 60 days is 24,569 and the stock's 52-week low/high is $0.25/$1.15.

AirWare Labs Corp. (AIRW)

Stock Commander, MyBestStockAlerts, PremiereStockAlerts, and Real Pennies reported earlier on AirWare Labs Corp. (AIRW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

AirWare Labs Corp. is an innovator in pioneering breathing devices and skin care products that enhance quality of life, personal health, and well-being. The Company sells its products through partners, including Wal-Mart, CVS, Walgreens, Albertsons, Drugstore.com, Acme, Shoppers, Shop n' Save, Farm Fresh, and individuals in the U.S., Canada, and Europe. AirWare Labs studies the effects of environmental factors on breathing and the human body. Additionally, it studies the scientifically shown benefits provided by the strategic use of therapeutic essential oils. AirWare Labs is headquartered in Scottsdale, Arizona.

The Company’s products address important personal health and quality of life issues providing antibacterial and therapeutic defense against airborne bacteria, viruses, and allergens, and also congestion, snoring, insomnia, nausea, headaches, and an athletic performance enhancing breathing aid that increases oxygen to fuel cells in the body.

Its products are marketed under the brand name of AIR®. AirWare’s product line-up includes air BREATHE, air ALLEREGY, air TRAVEL, air Essentials SLEEP/SNORE, air Essentials NAUSEA, air Essentials HEADACHE, air Essentials DECONGEST, and air SPORT.

AirWare Labs has introduced a new line of skin care products. These products use pharmaceutical-grade serums in a patented treatment system designed to enhance and provide youthful benefits to the skin. The first product in its skin care line uses a high-grade vitamin C serum combined with a patented protective shield to target facial wrinkles. Following this anti-wrinkle product, the Company will launch skin care systems to treat acne, scars, and warts. All of the products will be made available via a network of national distribution partners.

AirWare Labs has filed multiple new patent applications for an innovative nasal drug delivery system. This system will enable users to inhale precise doses of medication into the nasal cavity. The system will include AirWare’s patent-pending disposable sealed cartridge and patent-pending nasal insert system with insufflation plugins. Both of these can be filled with medication in powder form.

Recently, AirWare Labs announced that Katz Group Pharmacies, Inc. will offer AIR™ ALLERGY, AIR™ SLEEP SNORE, AIR™ DECONGEST and AIR™ BREATHE at 460 retail pharmacies across Central and Western Canada. Katz Group is one of Canada’s largest privately owned enterprises. It has pharmacy operations that include convenient Rexall and Rexall Pharma Plus locations in Canada.

AirWare Labs Corp. (AIRW), closed Thursday's trading session at $0.16, up 6.67%, on 138,700 volume with 12 trades. The average volume for the last 60 days is 19,273 and the stock's 52-week low/high is $0.0407/$0.25.

UMED Holdings, Inc. (UMED)

Today we are highlighting UMED Holdings, Inc. (UMED), here at the QualityStocks Daily Newsletter.

UMED Holdings, Inc. is a diversified holding company based in Fort Worth, Texas. It owns and operates businesses in a variety of industries. These include energy, oil and gas, aerospace, food and beverage, and mining. Its’ focus is to acquire businesses as wholly-owned subsidiaries that have stable, solid management; the immediate ability to grow exponentially with steady growth to follow, and an emphasis on emerging markets. UMED Holdings lists on the OTCQB.

UMED’s portfolio includes Greenway Innovative Energy, Inc. (Natural Gas-To-Liquid technology), Mamaki of Hawaii, Inc. (Mamaki tea plantation in Hawaii), Logistix Technology Systems, Inc. (technology and asset management tool for the Oil and Gas Industry), Jet Tech (aviation maintenance services company), and Arizona One, LLC (1,440 acres of Bureau of Land Management (BLM) land in Arizona).

The Company’s Greenway Innovative Energy, Inc. (GIE) wholly-owned subsidiary (a provider of proprietary, mobile Gas-to-Liquids (GTL) technology) entered into a Sponsored Research Agreement (SRA) in May 2014 with the University of Texas at Arlington to further refine and enhance its cutting-edge technology, which converts natural gas to clean synthetic fuels. The purpose of the Research Agreement with the University is to continually improve the existing Fisher-Tropsch synthesis process for the conversion of natural gas into liquid hydrocarbons, or synthetic fuels.

UMED Holdings announced in 2013 that it agreed to acquire the remaining 50 percent interest in Rig Support Services, Inc. (RSSI) (nka Logistix Technology Systems, Inc.). RSSI is a privately held Texas Corporation focused on developing a unique and valuable technology and asset management Tool for the Oil and Gas Industry.

UMED Holdings also announced in 2013 that it exercised its option under the terms of a pre-existing acquisition agreement to acquire the remaining 20 percent interest of Mamaki of Hawaii (MOH). MOH focuses on growing, harvesting, processing and marketing Mamaki herbal tea and extract. MOH has the only commercially approved and certified Mamaki tea farm in the world (26 acres). MOH is the owner and operator of Wood Valley Plantation, situated in the Kau district of the Big Island.

UMED Holdings, via its wholly-owned subsidiary Greenway Innovative Energy, announced in October 2014 the issuance by the US Patent Office of an additional patent that covers UMED’s mobile Gas-to-Liquids (GTL) conversion unit for converting natural gas to clean synthetic fuels. US patent number 8,795,597 covers claims associated with the process of transforming natural gas into hydrocarbon in a portable and mobile conversion unit.

This process involves removing sulfur from the natural gas and converting it into synthetic gas. The Greenway mobile Conversion Units will include a number of proprietary technological advancements, be relatively inexpensive to operate, dependable, long lived, and highly autonomous, necessitating minimal oversight.

UMED Holdings, Inc. (UMED), closed Thursday's trading session at $0.175, up 2.94%, on 75,740 volume with 9 trades. The average volume for the last 60 days is 21,534 and the stock's 52-week low/high is $0.10/$0.35.

Diamante Minerals, Inc. (DIMN)

Today we are reporting on Diamante Minerals, Inc. (DIMN), here at the QualityStocks Daily Newsletter.

Diamante Minerals, Inc. is a natural resources company concentrating on the diamond sector. It works to identify, explore, and develop first-class diamond bearing properties worldwide. The Company was formerly known as Oconn Industries Corp. It changed its name to Diamante Minerals, Inc. in April 2014. Diamante Minerals’ shares trade on the OTC Bulletin Board. The Company is focusing on developing the Batovi Diamond Project, located to the north of Paranatinga in Mato Grosso, Brazil.

The Batovi Diamond Project was optioned by Diamante Minerals and it is positioned 220 km north of the town of Paranatinga. This project represents a top-notch opportunity for the discovery of diamond bearing kimberlite intrusives. In addition, the Batovi Diamond Project has potential for the development of alluvial diamond production from diamondiferous gravels associated with the Rio Batovi drainage basin and its tributaries.

The landlocked province of Mato Grosso is in central Brazil. It has been the focus of much of Diamante Minerals exploration work in the nation. Surveys in this area have shown the presence of indicator minerals including garnets and chrome spinels. This represents a clear sign that kimberlite is a possibility.

Diamante Minerals has executed an agreement to form a joint venture (JV) valued at around $12 million with Mineracao Batovi Ltda., a mining and exploration company. The JV agreement considers the establishment of a new corporation to develop, finance, and operate a diamond exploration project situated to the north of Paranatinga in Mato Grosso, Brazil.

Diamante Minerals will contribute $1,000,000 in cash to a new JV company to be formed in Brazil (Newco), in return for a 20 percent equity interest. Mineracao Batovi will contribute the mineral claims underlying the Batovi Diamond Project to Newco in return for an 80 percent equity interest. Diamante Minerals may earn an additional 29 percent equity interest in Newco through funding $2,000,000 of Newco's exploration expenses no later than November 20, 2017.

Earlier this month, Diamante Minerals provided an update on its earlier announced Mineracao Batovi Diamond project. The Company will provide the $1 million cash investment directly to a JV partnership with mining and exploration company Mineracao Batovi Ltda., which is majority-owned by legendary geologist Mr. Charles Fipke.

Mr. Chad Ulansky, President and CEO of Diamante Minerals, said, "We are excited about the potential of this long-term project and particularly pleased to be working with Chuck Fipke, who is one of the industry's most successful and highly respected geologists, along with the talented team at Mineracao Batovi. The airborne survey of the claims area is anticipated to begin soon after the cash transfer is consummated."

Diamante Minerals, Inc. (DIMN), closed Thursday's trading session at $0.79, even for the day, on 200 volume with 2 trades. The average volume for the last 60 days is 14,077 and the stock's 52-week low/high is $0.432/$3.20.

graphic

The QualityStocks
Company Corner

graphic
graphic

One World Holdings, Inc. (OWOO)

The QualityStocks Daily Newsletter would like to spotlight One World Holdings, Inc. (OWOO). Today, One World Holdings, Inc. closed trading at $0.0066, up 94.12%, on 61,157,972 volume with 534 trades. The stock’s average daily volume over the past 60 days is 4,279,204, and its 52-week low/high is $0.0008/$0.05.

One World Holdings, Inc. subsidiary, The One World Doll Project , announced today that the company was featured in a June 17th Fortune.com article entitled, "Could A Realistic-Looking Doll Ever Dethrone Barbie?" "After recently securing a retail deal with Walmart that will place our dolls in over 2,900 stores this Christmas, I am very excited that Fortune.com chose to spotlight The One World Doll Project as a company that is making headway with mainstream retailers," stated Corinda Joanne Melton, CEO of One World Holdings, Inc.

One World Holdings, Inc. (OWOO) subsidiary, The One World Doll Project, was established in 2010 to make a significant positive cultural impact through the doll category, transcending global and ethnic borders to create positive self-image in young women and girl around the world. Led by worldwide famous doll designer Stacy McBride-Irby, The One World Doll Project team has more than 50 collective years in the doll and toy industry and is dedicated and armed with the experience to ensure that the dolls are of the highest quality and value.

In 2013, the company released its Prettie Girls!™ line of multi-cultural fashion dolls uniquely designed with individual physical attributes, personal stories and hobbies, and goals and inspirations. For young girls, the dolls are a friend, a partner in play, and a glimpse of their biggest, brightest dreams. For young women, the dolls are a symbol of who they are and what they can achieve. For doll connoisseurs, The One World Doll Project promises stylish works of art that will become a vital part of a growing collectors’ market.

The One World Doll Project also has a Signature Celebrity Collection of Prettie Girls! and in 2013 released its first celebrity collectors doll modeled after supermodel Cynthia Bailey from The Real Housewives of Atlanta. Since the release of the doll, it has been showcased with Synthia on The Arsenio Hall Show, What Happens Live with Andy Cohen and The Bethenny Show.

Using a web-based sales model, One World Holdings plans to quickly capture significant market share in the dolls and stuffed toys space. After securing a strong online presence, the company will focus on brick and mortar retailing as it moves toward the ultimate pursuit of expanding worldwide. The company has established distribution deals with Toys “R” Us, HEB, dollgenie.com, Tuckers Toy Shop, pattycakedoll.com, and has recently expanded its retail presence internationally with the People’s Pharmacy storechain in the Central American country of Belize. The Prettie Girls! Dolls have been featured in national and international media spotlights like CNN, The Wall Street Journal, Jet Magazine, Bloomberg.com, Parade.com, Dolls Magazine, The Toy Book, The Houston Chronicle and Houston Business Journal, and TheStreet.com. Disclaimer

One World Holdings, Inc. Company Blog

One World Holdings, Inc. News:

Fortune Article Highlights The One World Doll Project's Retail Success

Walmart Deal Secured; The One World Doll Project Founder Interviews With CEOLIVE.TV

The One World Doll Project To Launch New Prettie Girls! Tween Scene Collection At Walmart In October 2015

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $14.00, up 40.00%, on 9,572 volume with 27 trades. The stock’s average daily volume over the past 60 days is 449, and its 52-week low/high is $3.16/$15.00.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder

Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board

VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder

Save The World Air, Inc. (ZERO)

The QualityStocks Daily Newsletter would like to spotlight Save The World Air, Inc. (ZERO). Today, Save The World Air, Inc. closed trading at $0.39, up 5.41%, on 58,424 volume with 22 trades. The stock’s average daily volume over the past 60 days is 106,130, and its 52-week low/high is $0.3221/$0.839.

Save The World Air, Inc. (ZERO) (“STWA”) provides the global energy industry with patent-protected industrial equipment designed to deliver measurable performance improvements to crude oil pipelines. Developed in partnership with leading crude oil production and transportation entities, STWA’s high-value solutions address the enormous capacity inadequacies of domestic and overseas pipeline infrastructures that were designed and constructed prior to the current worldwide surge in oil production.

In support of our clients’ commitment to the responsible sourcing of energy and environmental stewardship, STWA combines scientific research with inventive problem solving to provide energy efficiency ‘clean tech’ solutions to bring new efficiencies and lower operational costs to the upstream, midstream and gathering sectors. STWA’s flagship product, AOT (Applied Oil Technology) improves the economics of transporting crude oil by reducing the viscosity of oil in pipelines. Once deployed on pipeline pumping stations, production and transportation companies benefit from the safer, more cost-effective delivery of greater volumes of oil while reducing energy consumption at pumping stations and lowering CO2 emissions.

The AOT technology is the result of years of research conducted at Temple University (Philadelphia, Penn.) and is the world’s first ASME-certified industrial hardware to use the principles of electrorheology, the study of applying non-uniform electrical fields to change the mechanical behavior of fluids, to significantly reduce the viscosity of crude oil within pipelines during maximum flow conditions. Field tested by the U.S. Department of Energy, independent testing laboratories such as ATS RheoSystems and fabricated to exacting industry standards by STWA’s supply chain partners, the efficacy of AOT to increase flow rates, prevent bottlenecks, reduce pump station power consumption, enhance pipeline integrity and optimize flow assurance has been proven repeatedly in the lab and on a 300,000 barrel per day pipeline.

STWA is also commercializing STWA Joule Heat, an energy-efficient technology for heating crude oil in pipelines to improve flow. Unlike traditional trace heating systems which generate heat via a resistive trace heating element which transfers energy into the oil, the STWA solution applies an electrical field directly to oil, generating heat within the flow itself. The result is optimal heat conductivity and performance with less power and in a smaller form factor.

Guided by a dynamic management team led by Greggory Bigger, Chief Executive Officer, Chairman and a strong independent board of directors of energy industry veterans, STWA is a revenue generating company with a solid cash position, clean balance sheet and a proven ability to develop and deliver industrial-grade equipment that support the company’s mission and enhance shareholder value. As the exclusive licensee of oil viscosity reduction processes developed at Temple University and owner of 48 worldwide patents related to the use of electricity to change the mechanical behavior of oil and liquid natural gas, STWA is well-positioned to capitalize on the explosive growth opportunities in the global crude oil production and transportation sector. More information is available at: www.stwa.com. Disclaimer

Save The World Air, Inc. Company Blog

Save The World Air, Inc. News:

STWA Deploys Joule Heat Direct Heating System on Gathering Line for Crude Oil Pipeline in Uintah Basin

STWA Congratulates Pipeline Research Council International on New Technology Development Center

STWA Announces Preliminary AOT(TM) Test Results From Southern Research Institute

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.046, even for the day, on 97,184 volume with 17 trades. The stock’s average daily volume over the past 60 days is 774,153, and its 52-week low/high is $0.045/$0.148.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.

The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.

In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation to Present at International Society for Cellular Therapy Annual Meeting

International Stem Cell Corporation Announces 2015 First Quarter Results

International Stem Cell Corporation Publishes Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation

MIT Holding (MITD)

The QualityStocks Daily Newsletter would like to spotlight MIT Holding (MITD). Today, MIT Holding closed trading at $0.03, even for the day, on 500 volume with 1 trade. The stock’s average daily volume over the past 60 days is 8,651, and its 52-week low/high is $0.03/$0.29.

MIT Holding (MITD), through its agents, facilitators and contractual obligations, offers professional outpatient medical care with ambulatory infusion therapies, home infusion services, and medical equipment delivery. The company is also pursuing government contacts to obtain approval to import pharmaceutical products into the Americas.

In support of these core services, MIT Holding provides expert legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act; offers travel and transportation services of medically challenged patients for medical needs and personal travel; and through its contracts is approved to, conduct and administer FDA clinical trials.

Collectively, these services contribute to MIT Holding’s strategy to provide custom prescription solutions in a variety of methods and generate multiple revenue streams. Following a successful reorganization initiative in January, 2014, MIT Holding is positioned to achieve 32% minimum net profits and has maintained profitability in its fiscal second and third quarters. This profitability validates the company’s business model and its approach to the evolving Affordable Health Care Act and its impact on the health services industry.

MIT Holding meets and/or exceeds major U.S. health insurance requirements and is therefore able to direct bill and receive payments from carriers on behalf of the patient its agents and its facilitators. This ability marks an important step in the company’s goal of developing the first-of-its-kind seamless transition for patient needs from hospital discharge to complete home recovery. This and other corporate initiatives are spearheaded by a management team committed to building shareholder value, revenues and corporate expansion while providing viable solutions to the perpetual changes in the health care sector. Disclaimer

MIT Holding Company Blog

MIT Holding News:

MIT Holding Achieves Positive Net Income From Operations in 2014

MIT Holding (MITD) Launches New Website with Investor Relations Suite

MIT Holding, Inc. Names Tommy J. Duncan as President

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

QualityStocks
(OWOO)

2.

TinyGems
(VSTA)

3.

Greenbackers
(PSID)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251